Influence of genetic polymorphisms in the folate pathway on toxicity after high-dose methotrexate treatment in pediatric osteosarcoma

Blood Research

Volumn 51, Issue 1, 2016, Pages 50-57

  Park, Jeong A ^a   Shin, Hee Young ^b  

^a Inje University College of Medicine   (South Korea)

^b Seoul National University Children's Hospital   (South Korea)

Author keywords

Methotrexate; Osteosarcoma; Pediatric; Single nucleotide polymorphism; Toxicity

Indexed keywords

5 AMINOIMIDAZOLE 4 CARBOXAMIDE RIBONUCLEOTIDE FORMYLTRANSFERASE; 5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); BIOLOGICAL MARKER; FOLIC ACID; GENOMIC DNA; METHOTREXATE; REDUCED FOLATE CARRIER; RIBONUCLEOTIDE; UNCLASSIFIED DRUG;

ADOLESCENT; ARTICLE; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; DNA EXTRACTION; DRUG BLOOD LEVEL; DRUG MEGADOSE; DRUG METABOLISM; DRUG MONITORING; DRUG SAFETY; FEMALE; GENE AMPLIFICATION; GENETIC POLYMORPHISM; GENOTYPING TECHNIQUE; HUMAN; MALE; MUCOSA INFLAMMATION; NEPHROTOXICITY; OSTEOSARCOMA; PHARMACOGENOMICS; SINGLE NUCLEOTIDE POLYMORPHISM;

EID: 84962198360     PISSN: 2287979X     EISSN: 22880011     Source Type: Journal    
DOI: 10.5045/br.2016.51.1.50     Document Type: Article

References (30)

1. Relling MV, Fairclough D, Ayers D, et al. Patient characteristics associated with high-risk methotrexate concentrations and toxicity. J Clin Oncol 1994;12:1667-72.
2. Rask C, Albertioni F, Bentzen SM, Schroeder H, Peterson C. Clinical and pharmacokinetic risk factors for high-dose methotrexateinduced toxicity in children with acute lymphoblastic leukemia-a logistic regression analysis. Acta Oncol 1998;37:277-84.
3. Johansson ÅM, Hill N, Perisoglou M, Whelan J, Karlsson MO, Standing JF. A population pharmacokinetic/pharmacodynamic model of methotrexate and mucositis scores in osteosarcoma. Ther Drug Monit 2011;33:711-8.
4. de Jonge R, Tissing WJ, Hooijberg JH, et al. Polymorphisms in folate-related genes and risk of pediatric acute lymphoblastic leukemia. Blood 2009;113:2284-9.
5. Gorlick R, Goker E, Trippett T, Waltham M, Banerjee D, Bertino JR. Intrinsic and acquired resistance to methotrexate in acute leukemia. N Engl J Med 1996;335:1041-8.
6. Stamp LK, Roberts RL. Effect of genetic polymorphisms in the folate pathway on methotrexate therapy in rheumatic diseases. Pharmacogenomics 2011;12:1449-63.
7. Meyers PA, Schwartz CL, Krailo M, et al. Osteosarcoma: a randomized, prospective trial of the addition of ifosfamide and/or muramyl tripeptide to cisplatin, doxorubicin, and high-dose methotrexate. J Clin Oncol 2005;23:2004-11.
8. Marina N, Bielack S, Whelan J, et al. International collaboration is feasible in trials for rare conditions: the EURAMOS experience. Cancer Treat Res 2009;152:339-53.
9. Trotti A, Colevas AD, Setser A, et al. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Semin Radiat Oncol 2003;13:176-81.
10. Perez C, Wang YM, Sutow WW, Herson J. Significance of the 48-hour plasma level in high-dose methotrexate regimens. Cancer Clin Trials 1978;1:107-11.
11. Shimasaki N, Mori T, Samejima H, et al. Effects of methylenetetrahydrofolate reductase and reduced folate carrier 1 polymorphisms on high-dose methotrexate-induced toxicities in children with acute lymphoblastic leukemia or lymphoma. J Pediatr Hematol Oncol 2006;28:64-8.
12. Imanishi H, Okamura N, Yagi M, et al. Genetic polymorphisms associated with adverse events and elimination of methotrexate in childhood acute lymphoblastic leukemia and malignant lymphoma. J Hum Genet 2007;52:166-71.
13. Laverdière C, Chiasson S, Costea I, Moghrabi A, Krajinovic M. Polymorphism G80A in the reduced folate carrier gene and its relationship to methotrexate plasma levels and outcome of childhood acute lymphoblastic leukemia. Blood 2002;100:3832-4.
14. Huang L, Tissing WJ, de Jonge R, van Zelst BD, Pieters R. Polymorphisms in folate-related genes: association with side effects of high-dose methotrexate in childhood acute lymphoblastic leukemia. Leukemia 2008;22:1798-800.
15. Zhao R, Seither R, Brigle KE, Sharina IG, Wang PJ, Goldman ID. Impact of overexpression of the reduced folate carrier (RFC1), an anion exchanger, on concentrative transport in murine L1210 leukemia cells. J Biol Chem 1997;272:21207-12.
16. Matherly LH, Goldman DI. Membrane transport of folates. Vitam Horm 2003;66:403-56.
17. Holmboe L, Andersen AM, Mørkrid L, Slørdal L, Hall KS. High dose methotrexate chemotherapy: pharmacokinetics, folate and toxicity in osteosarcoma patients. Br J Clin Pharmacol 2012;73: 106-14.
18. Widemann BC, Adamson PC. Understanding and managing methotrexate nephrotoxicity. Oncologist 2006;11:694-703.
19. Evans WE, Pratt CB, Taylor RH, Barker LF, Crom WR. Pharmacokinetic monitoring of high-dose methotrexate. Early recognition of high-risk patients. Cancer Chemother Pharmacol 1979;3:161-6.
20. Stoller RG, Hande KR, Jacobs SA, Rosenberg SA, Chabner BA. Use of plasma pharmacokinetics to predict and prevent methotrexate toxicity. N Engl J Med 1977;297:630-4.
21. Bernard S, Etienne MC, Fischel JL, Formento P, Milano G. Critical factors for the reversal of methotrexate cytotoxicity by folinic acid. Br J Cancer 1991;63:303-7.
22. Fabre I, Fabre G, Goldman ID. Polyglutamylation, an important element in methotrexate cytotoxicity and selectivity in tumor versus murine granulocytic progenitor cells in vitro. Cancer Res 1984;44:3190-5.
23. Gervasini G. Polymorphisms in methotrexate pathways: what is clinically relevant, what is not, and what is promising. Curr Drug Metab 2009;10:547-66.
24. Schmiegelow K. Advances in individual prediction of methotrexate toxicity: a review. Br J Haematol 2009;146:489-503.
25. Ross CJ, Visscher H, Rassekh SR, et al. Pharmacogenomics of serious adverse drug reactions in pediatric oncology. J Popul Ther Clin Pharmacol 2011;18:e134-51.
26. Stringer AM, Gibson RJ, Bowen JM, Keefe DM. Chemotherapyinduced modifications to gastrointestinal microflora: evidence and implications of change. Curr Drug Metab 2009;10:79-83.
27. Pico JL, Avila-Garavito A, Naccache P. Mucositis: Its occurrence, consequences, and treatment in the oncology setting. Oncologist 1998;3:446-51.
28. Epstein JB. Mucositis in the cancer patient and immunosuppressed host. Infect Dis Clin North Am 2007;21:503-22, vii.
29. de Koning BA, van Dieren JM, Lindenbergh-Kortleve DJ, et al. Contributions of mucosal immune cells to methotrexate-induced mucositis. Int Immunol 2006;18:941-9.
30. Gregers J, Christensen IJ, Dalhoff K, et al. The association of reduced folate carrier 80G>A polymorphism to outcome in childhood acute lymphoblastic leukemia interacts with chromosome 21 copy number. Blood 2010;115:4671-7.